4.6 Article

Resting-State Network Alterations Differ between Alzheimer's Disease Atrophy Subtypes

Journal

CEREBRAL CORTEX
Volume 31, Issue 11, Pages 4901-4915

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/cercor/bhab130

Keywords

Alzheimer's disease; brain structure; graph theory; independent component analysis; resting-state connectivity

Categories

Funding

  1. Alzheimer's Disease Neuroimaging Initiative (ADNI
  2. National Institutes of Health Grant) [U01 AG024904]
  3. National Institute on Aging
  4. National Institute of Biomedical Imaging and Bioengineering
  5. Abbott
  6. Alzheimer's Association
  7. Alzheimer's Drug Discovery Foundation
  8. Amorfix Life Sciences Ltd
  9. AstraZeneca
  10. Bayer HealthCare
  11. BioClinica, Inc.
  12. Biogen Idec Inc.
  13. BristolMyers Squibb Company
  14. Eisai Inc.
  15. Elan Pharmaceuticals Inc.
  16. Eli Lilly and Company
  17. F. Hoffmann-La Roche Ltd
  18. company Genentech, Inc.
  19. GE Healthcare
  20. Innogenetics, N.V.
  21. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  22. Johnson & Johnson Pharmaceutical Research & Development LLC.
  23. Medpace, Inc.
  24. Merck Co., Inc.
  25. Meso Scale Diagnostics, LLC.
  26. Novartis Pharmaceuticals Corporation
  27. Pfizer Inc.
  28. Servier
  29. Synarc Inc.
  30. Takeda Pharmaceutical Company
  31. Canadian Institutes of Health Research
  32. National Institutes of Health (NIH) [P30 AG010129, K01 AG030514]
  33. German Center for Neurodegenerative Diseases (Deutsches Zentrum fur Neurodegenerative Erkrankungen, DZNE) [BN01]

Ask authors/readers for more resources

By analyzing the brain network properties of various AD atrophy subtypes, we identified distinct differences in functional connectivity networks accompanied by CSF biomarker and cognitive differences.
Several Alzheimer's disease (AD) atrophy subtypes were identified, but their brain network properties are unclear. We analyzed data from two independent datasets, including 166 participants (103 AD/63 controls) from the DZNE-longitudinal cognitive impairment and dementia study and 151 participants (121 AD/30 controls) from the AD neuroimaging initiative cohorts, aiming to identify differences between AD atrophy subtypes in resting-state functional magnetic resonance imaging intra-network connectivity (INC) and global and nodal network properties. Using a data-driven clustering approach, we identified four AD atrophy subtypes with differences in functional connectivity, accompanied by clinical and biomarker alterations, including a medio-temporal-predominant (S-MT), a limbic-predominant (S-L), a diffuse (S-D), and a mild-atrophy (S-MA) subtype. S-MT and S-D showed INC reduction in the default mode, dorsal attention, visual and limbic network, and a pronounced reduction of global efficiency and decrease of the clustering coefficient in parietal and temporal lobes. Despite severe atrophy in limbic areas, the S-L exhibited only marginal global network but substantial nodal network failure. S-MA, in contrast, showed limited impairment in clinical and cognitive scores but pronounced global network failure. Our results contribute toward a better understanding of heterogeneity in AD with the detection of distinct differences in functional connectivity networks accompanied by CSF biomarker and cognitive differences in AD subtypes.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available